Retrospective Study Looking at Cinacalcet in the Management of Hyperparathyroidism after Kidney Transplantation
Table 2
Baseline characteristics according to cinacalcet status 1 year after kidney transplantation.
Characteristics
No cinacalcet
Cinacalcet
value
Age (years)
ns
Male
4 (67%)
9 (82%)
ns
Body mass index (kg/m2)
0.105
Ethnicity
Caucasian
3 (50%)
6 (55%)
ns
Black
2 (33%)
4 (36%)
ns
Presumptive cause of ESRD
Diabetic nephropathy
1 (17%)
3 (27%)
ns
Hypertensive nephrosclerosis
2 (33%)
3 (27%)
ns
Polycystic renal disease
1 (17%)
3 (27%)
ns
Other
2 (33%)
2 (18%)
ns
Comorbidities
Hypertension
6 (100%)
11 (100%)
ns
Dyslipidemia
4 (67%)
9 (82%)
ns
Diabetes
1 (17%)
4 (36%)
ns
Coronary artery disease
2 (33%)
4 (36%)
ns
Heart failure
0 (0%)
6 (55%)
0.043
Smoking
1 (17%)
1 (9%)
ns
Dialysis modality
In-center hemodialysis
4 (67%)
6 (55%)
ns
Home hemodialysis
1 (17%)
3 (27%)
ns
Peritoneal dialysis
1 (17%)
2 (18%)
ns
Time spent on dialysis (years)
ns
Baseline biochemistry
PTH (pmol/L)
0.102
Corrected calcium (mmol/L)
ns
Phosphate (mmol/L)
0.196
PTH: parathyroid hormone; ns: not significant; values < 0.05 are considered statistically significant; values < 0.2 are indicated because variables were included in logistic regression model; continuous variables are expressed as mean ± standard deviation; categorical variables are expresses as count (%).
